




EMLc

ATC codes: [P01AC01](#)

Indication	Amoebiasis <span style="background-color: #00a651; color: white; padding: 2px;">ICD11 code: 1A36.Z</span>
INN	Diloxanide
Medicine type	Chemical agent
List type	Core (EML) (EMLc)
Formulations	Oral > Solid: 500 mg (furoate)
EML status history	First added in 1977 ( <a href="#">TRS 615</a> ) Changed in 1979 ( <a href="#">TRS 641</a> ) Changed in 1982 ( <a href="#">TRS 685</a> ) Changed in 1984 ( <a href="#">TRS 722</a> ) Changed in 2003 ( <a href="#">TRS 920</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2011 ( <a href="#">TRS 965</a> )
Sex	All
Age	Also recommended for children
Weight restriction	> 25 kg
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Diloxanide</a> 
DrugBank	<a href="#">Diloxanide</a> 

## Summary of evidence and Expert Committee recommendations

A review of the evidence supporting treatment of neglected tropical diseases in children was considered by the Expert Committee in 2011. The review focused on antischistosomal, antitrepatode, anti-amoebic, anti giardiasis and antitrypanosomal medicines. For anti-amoebic and anti giardiasis medicines, no changes to the current listing of diloxanide were made.

